心肌梗塞的管理:未来的新兴范式
Vandan D Upadhyaya1, Christopher Wong2, Ramzan M Zakir2
1Hackensack Meridian Health -Jersey Shore University Medical Center, Neptune City, New Jersey, US.
Methodist DeBakey cardiovascular journal
|August 26, 2024
概括
减少心脏病发作的大小可以预防心力衰竭. 左心室卸载策略,包括微轴流装置,有望改善急性心肌梗塞患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 心血管研究研究心血管研究
- 医疗干预 医疗干预
背景情况:
- 急性ST段升高心肌梗塞 (STEMI) 管理已取得进展,但心力衰竭患病率仍然很高.
- 减少心脏病发作的大小是改善急性冠状动脉综合征后结果的关键策略.
- 左心室 (LV) 卸载已经成为限制心脏病发作大小的潜在机制.
研究的目的:
- 审查关于急性心肌梗塞中心脏病发作大小减小的临床数据.
- 突出正在进行的临床试验,探索心肌梗塞管理的新治疗方法.
- 评估LV卸载在改善急性心肌梗塞患者治疗结果中的作用.
主要方法:
- 对临床试验数据的审查,重点关注心脏病发作大小的减少.
- 对微轴流量装置在LV卸载中的当代使用情况的分析.
- 检查证据,以改善急性心肌梗塞与心脏性休克的死亡率.
主要成果:
- 专注于减少心脏病发作大小的新兴范式表明,在急性冠状动脉综合征后降低心力衰竭发病率方面具有前途.
- LV 卸载,特别是微轴流装置,已经显示出可能改善心肌梗塞急性死亡率,心脏性休克复杂化.
- 临床数据表明,减少心脏病发作大小作为治疗目标的证据.
结论:
- 限制心脏病发作的大小是治疗急性心肌梗塞和预防心力衰竭的关键治疗目标.
- 左心室卸载是一种有前途的策略,有可能改善严重急性心肌梗塞的死亡率.
- 目前正在进行的临床试验正在探索减少心脏病发作大小的新方法,为患者提供新的希望.
更多相关视频
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.1K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.4K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:17Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
464
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464